Oseltamivir

CHEMBL1229 Phase 4 Onaylandı Small molecule

Half-Life

6-10 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

312.4 g/mol

LogP

1.1

Phase

4

An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

Moleküler Ağırlık

312,4050 g/mol

LogP

1,10

TPSA

90,70 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Respiratory Disease Pain Management Asthma Chronic Obstructive Pulmonary Disease Insomnia Gastroesophageal Reflux Disease Systemic Lupus Erythematosus Obesity Hypertension Chronic Pain Heart Failure

İlaç Sınıfları

J — J - Antiinfectives for Systemic Use

Etki Mekanizması

Neuraminidase inhibitor preventing viral release from host cells.

Pharmacokinetics (PK)

Half-Life 6-10 hours

Pharmacodynamics (PD)

Mekanizma

Neuraminidase inhibitor preventing viral release from host cells.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1

Molecular Formula

C16H28N2O4

HBD / HBA

2 / 5

Döndürülebilir Bağlar

8

Ağır Atomlar

22

ABCB1 (P-glycoprotein) Substrate

Primary Target

Minor Oseltamivir + Warfarin

Oseltamivir does not appear to meaningfully alter warfarin pharmacokinetics; however, the febrile illness being treated may independently elevate INR, which can be mistakenly attributed to the antiviral.

Minor Oseltamivir + Methotrexate

Both oseltamivir carboxylate and methotrexate rely on renal tubular secretion via OAT transporters; theoretically, competition could reduce elimination of either drug, though clinical evidence of a significant interaction is limited.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

Neuraminidase inhibitor preventing viral release from host cells.

Key pharmacokinetic parameters for Oseltamivir: Half-life: 6-10 hours.

Yes, Oseltamivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Amoxicillin Small molecule Azithromycin Small molecule Ciprofloxacin Small molecule Doxycycline Small molecule

Same Target

Aspirin Small molecule Metformin Small molecule Atorvastatin Small molecule Omeprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1229. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 65028. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Oseltamivir PillFYI'da

Yapı

Hızlı Veriler

Class: J - Antiinfectives for Systemic Use
Formül: C16H28N2O4
Eş Anlamlılar: 3

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Oseltamivir

Terapötik Alanlar

İlaç Sınıfları

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No side effects recorded

Sıkça Sorulan Sorular

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget